Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
|
|
Chemomab Therapeutics Ltd. (ANCN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"6-K",
"Unaudited Audited Current assets Cash and cash equivalents 10,382 13,519 Short term bank deposits 16,207 26,374 Restricted cash 74 77 Other receivables and prepaid expenses 1,042 1,766 Total current assets 27,705 41,736 Non-current assets Long term prepaid expenses 646 733 Property and equipment, net 338 367 Operating lease right-of-use assets 160 227 Total non-current assets 1,144 1,327 Total assets 28,849 43,063 Current liabilities Trade payables 2,347 1,688 Accrued expenses 2,503 3,378 Employee and related expenses 1,867 1,560 Operating lease liabilities 108 123 Total current liabilities 6,825 6,749 Non-current liabilities Operating lease liabilities - long term 33 91 Total non-current liabilities 33 91 Commitments and contingent liabilities 3 Total liabilities 6,858 6,840 Shareholders'...",
"CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS",
"TEL AVIV, Israel, August 14, 2023 ─ Chemomab Therapeutics Ltd. , , a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the second quarter ended June 30, 2023, and provided a corporate update. “I am pleased to report that the company continued to make good progress during the second quarter,” said Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab. “In June, the Board of Directors re-appointed me to the CEO position and re-appointed then Vice President of Finance Sigal Fattal as Chief Financial Officer. Our extensive prior experience in these roles and ongoing active involvement in company management have made..." |
|
| 08/08/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 07/03/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 06/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/19/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 03/21/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 03/21/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/20/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/22/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 01/13/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 01/11/2023 |
8-K
| Quarterly results |
| 01/05/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/03/2023 |
8-K
| Quarterly results |
| 11/29/2022 |
8-K/A
| Quarterly results |
| 11/17/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 11/16/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/15/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/12/2022 |
8-K
| Quarterly results |
| 06/21/2022 |
8-K
| Quarterly results |
| 06/08/2022 |
8-K
| Quarterly results |
| 06/01/2022 |
8-K
| Quarterly results |
| 05/31/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/12/2022 |
8-K
| Quarterly results |
| 04/28/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/25/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/30/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/09/2022 |
8-K
| Quarterly results |
| 02/11/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
|
|
|